All Updates

All Updates

icon
Filter
FDA approval
Roche receives US FDA approval for Vabysmo PFS to treat retinal conditions
Longevity Tech
Jul 5, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Longevity Tech

Longevity Tech

Jul 5, 2024

Roche receives US FDA approval for Vabysmo PFS to treat retinal conditions

FDA approval

  • Roche has received US FDA approval for Vabysmo, an antibody-filled preloaded syringe, to treat neovascular or "wet" age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). Although pricing details were not disclosed, the product will be available soon.

  • Vabysmo, also known as "faricimab," is the only bispecific antibody approved for treating the eye. The company claims that it has demonstrated rapid and robust vision improvements and retinal drying in nAMD, DME, and RVO. This single-use preloaded syringe can be readily used by retina specialists.

  • Analyst QuickTake: To date, Vabysmo has been approved in over 95 countries for nAMD and DME, and many other countries including the US and Japan for RVO. Several other health authorities worldwide are reviewing the product for approval. Over 4 million doses of Vabysmo have been distributed globally since its initial US approval in 2022.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.